XNK Therapeutics AB has appointed Dr. Peter Hovstadius as its new Chief Medical Officer, effective immediately. He will join the company’s management team, while Dr. Johan Aschan, who is retiring from his CMO role, will remain as Senior Medical Advisor. With Dr. Hovstadius at the helm of its medical operations, XNK is poised to continue its commitment to providing the best medical care possible.
Dr. Hovstadius is a highly accomplished medical expert, having received his MD from Uppsala University in 1992 and his PhD in Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment in 2005. He is also a specialist in Clinical Pharmacology, and has held Medical Director positions at several global research-based pharmaceutical companies. During his career he has been a part of launching over 20 new therapies, and spent eight years as Chief Scientific Officer at Novartis in the Nordics, leading clinical research operations for phase I-IV programs, medical affairs, regulatory affairs and drug safety. Most recently, he has taken on the pioneering role as Chief Innovation Officer at Novartis, establishing new industry collaborations between pharma and innovative startup companies in the expanding e-Health sector. Dr. Hovstadius’ impressive accomplishments and dedication to driving innovation have made him a leader in the medical field.
Peter is a valuable addition to the XNK team, bringing a wealth of experience in oncology and clinical trials development from both academia and the pharma industry. His expertise will be essential in advancing our project pipeline and fostering collaborations with the scientific community. We are grateful to Johan Liwing, our CEO, for his contribution to XNK and are thankful that he will continue to provide his counsel as Senior Medical Advisor.
Dr. Peter Hovstadius is thrilled to be at the forefront of XNK’s innovative NK cell-based therapy research. He is eager to further develop the company’s clinical programs and increase collaborations with other leading research institutions. It’s an exciting time for XNK as they strive to revolutionize the field.
About XNK Therapeutics AB
XNK Therapeutics is pioneering the next generation of cancer treatments with its revolutionary autologous NK cell-based therapies. Utilizing its proprietary technology platform, XNK Therapeutics is at the forefront of developing new treatments for cancers in settings where allogeneic cell products are not viable. With its headquarters in Stockholm, Sweden, XNK Therapeutics is poised to revolutionize cancer care and provide hope to those affected by this devastating disease.